Pimavanserin Tartrate
Brand name: Nuplazid
Rank #84 of 500 drugs by total cost
$219.0M
Total Cost
51,053
Total Claims
$219.0M
Total Cost
1,775
Prescribers
$4,291
Cost per Claim
1,569
Beneficiaries
54,213
30-Day Fills
$123K
Avg Cost/Provider
29
Avg Claims/Provider
About Pimavanserin Tartrate
Pimavanserin Tartrate (sold as Nuplazid) was prescribed 51,053 times by 1,775 Medicare Part D providers in 2023, costing the program $219.0M. At $4,291 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 81 | Emtricitabine/Tenofov Alafenam (Descovy) | $222.4M | 94,580 |
| 82 | Immun Glob G(Igg)/Gly/Iga Ov50 (Gammagard Liquid) | $222.1M | 22,768 |
| 83 | Immun Glob G(Igg)/Pro/Iga 0-50 (Hizentra) | $222.0M | 21,722 |
| 84 | Pimavanserin Tartrate (Nuplazid) | $219.0M | 51,053 |
| 85 | Metformin Hcl (Metformin Hcl) | $218.8M | 14,222,346 |
| 86 | Diclofenac Sodium (Diclofenac Sodium) | $216.8M | 3,418,852 |
| 87 | Abatacept (Orencia) | $216.6M | 36,753 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology